Frontiers in nonclinical drug development: biosimilars

Area of Science:

• Biopharmaceutical development
• Drug manufacturing
• Regulatory science

Background:

• Biopharmaceuticals, manufactured via recombinant DNA technology, present complex production challenges compared to small molecule drugs.
• Expiring patents for originator biopharmaceuticals create opportunities for the development of biosimilars.
• Biosimilars aim to enhance patient access and foster market competition through affordability.

Purpose of the Study:

• To define biosimilars and their regulatory context.
• To compare and contrast biosimilar production with small molecule drugs, generic drugs, and other biological drugs.
• To describe the fundamental principles of nonclinical development for monoclonal antibody biosimilars.

Main Methods:

• Comparative analysis of drug production processes (biopharmaceuticals vs. small molecules, generics, biologics).
• Review of biosimilar development principles.
• Description of nonclinical study designs for monoclonal antibody biosimilars.

Main Results:

• Biosimilars are highly similar to reference biological products, with no clinically meaningful differences.
• Production processes for biosimilars are distinct from generic drugs but share similarities with originator biologics.
• Nonclinical programs for monoclonal antibody biosimilars focus on demonstrating similarity and safety.

Conclusions:

• Biosimilars represent a crucial pathway to increasing access to complex biologic medicines.
• Understanding the nuances of biosimilar production and development is essential for regulatory approval and market integration.
• The nonclinical evaluation of biosimilars, particularly monoclonal antibodies, is critical for establishing safety and efficacy profiles.